Latest Pharma Insights
Trump 100% Tariffs On Drugs Make Big Pharma’s Negotiations A Smart Play
Most big pharmas – the companies that tend to have a global manufacturing network – are exempt from the US government’s Section 232 tariffs on pharmaceuticals.
Scrip - April 2, 2026
Most big pharmas – the companies that tend to have a global manufacturing network – are exempt from the US government’s Section 232 tariffs on pharmaceuticals.
Scrip - April 2, 2026
March Surge Lifts First Quarter M&A Totals To Recent Highs
The biopharma sector announced 41 merger-and-acquisition deals during Q1 2026, according to Evaluate, with a late March run of multibillion-dollar bids.
Scrip - April 2, 2026
The biopharma sector announced 41 merger-and-acquisition deals during Q1 2026, according to Evaluate, with a late March run of multibillion-dollar bids.
Scrip - April 2, 2026
US Consumer Health People News: Primo For Griffey, HealthyBaby First President, More
Primo scores on hydration with Griffey; HealthyBaby names first president; Supergoop! Expands executive office with HR chief; and interim CFO at Nu Skin.
HBW Insight - April 2, 2026
Primo scores on hydration with Griffey; HealthyBaby names first president; Supergoop! Expands executive office with HR chief; and interim CFO at Nu Skin.
HBW Insight - April 2, 2026
Beam Preps For Commercialization Of Risto-Cel As Full Data Published
The publication included additional details on a patient whose death in the study had drawn analysts’ attention, revealing that he had a history of vaping as well as other conditions.
Scrip - April 2, 2026
The publication included additional details on a patient whose death in the study had drawn analysts’ attention, revealing that he had a history of vaping as well as other conditions.
Scrip - April 2, 2026
Execs On The Move: March 23–27, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 2, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 2, 2026
Whoop Raises $575M At $10.1Bn Valuation With Abbott on Board As Oura And Google Close In
The company, which ships to 56 countries and operates in six languages, said it ended last year booking deals at an annual pace of about $1.1 billion– up 103% year over year – and said it is hiring for more than 600 new roles globally in 2026.
Medtech Insight - April 2, 2026
The company, which ships to 56 countries and operates in six languages, said it ended last year booking deals at an annual pace of about $1.1 billion– up 103% year over year – and said it is hiring for more than 600 new roles globally in 2026.
Medtech Insight - April 2, 2026
Force Majeure, 35% Spike In Plastics Costs: Middle East Conflict Hits Medical Supply Chains
Five weeks into the Middle Eastern war, petrochemical force majeure declarations are being filed, prices for a key petrochemical used in plastics are up 35% and the supply chains that produce IV bags, syringes and catheters are under compounding pressure.
Medtech Insight - April 2, 2026
Five weeks into the Middle Eastern war, petrochemical force majeure declarations are being filed, prices for a key petrochemical used in plastics are up 35% and the supply chains that produce IV bags, syringes and catheters are under compounding pressure.
Medtech Insight - April 2, 2026
Enzymatica Partners With Stada For German ColdZyme Launch
Stada will launch Enzymatica's virus-blocking oral spray ColdZyme under its own brand in Germany and Austria during the 2026/27 cold & flu season.
HBW Insight - April 2, 2026
Stada will launch Enzymatica's virus-blocking oral spray ColdZyme under its own brand in Germany and Austria during the 2026/27 cold & flu season.
HBW Insight - April 2, 2026
Roivant Shrugs Off Batoclimab Phase III Failure in TED
Immunovant’s first-generation FcRn inhibitor, batoclimab, has failed a pair of Phase III studies, prompting the company to undertake a review of the drug’s development program.
Scrip - April 2, 2026
Immunovant’s first-generation FcRn inhibitor, batoclimab, has failed a pair of Phase III studies, prompting the company to undertake a review of the drug’s development program.
Scrip - April 2, 2026
Alto’s Schizophrenia Failure Reinforces Its Depression Drive
Alto Neuroscience’s ALTO-101 has missed significance in a proof-of-concept study in schizophrenia patients, prompting the firm to stand even more squarely behind its lead depression asset, ALTO-207.
Scrip - April 2, 2026
Alto Neuroscience’s ALTO-101 has missed significance in a proof-of-concept study in schizophrenia patients, prompting the firm to stand even more squarely behind its lead depression asset, ALTO-207.
Scrip - April 2, 2026
Who’s Hired? Watson Returns As Apotex CEO
The latest off-patent industry appointments have seen Jeff Watson return as president and CEO of Apotex and Pamela Hoffman take the title of CEO of Padagis, while Australia’s GBMA and Medicines for Ireland have announced new leadership.
Generics Bulletin - April 2, 2026
The latest off-patent industry appointments have seen Jeff Watson return as president and CEO of Apotex and Pamela Hoffman take the title of CEO of Padagis, while Australia’s GBMA and Medicines for Ireland have announced new leadership.
Generics Bulletin - April 2, 2026
Teva Clarifies Operations Stable After Neot Hovav Strike
Teva has confirmed no operational impact after a missile-related incident near its Neot Hovav site, countering reports that raised concerns over supply chain risk and manufacturing resilience amid escalating regional tensions.
Generics Bulletin - April 2, 2026
Teva has confirmed no operational impact after a missile-related incident near its Neot Hovav site, countering reports that raised concerns over supply chain risk and manufacturing resilience amid escalating regional tensions.
Generics Bulletin - April 2, 2026
Amarin Insists Skinny Labels Are Not A Safe Harbor
Amarin is asking the US Supreme Court to uphold the Federal Circuit in its Hikma dispute, arguing that skinny-label carve-outs do not shield generics from inducement liability when broader marketing conduct encourages patented uses.
Generics Bulletin - April 2, 2026
Amarin is asking the US Supreme Court to uphold the Federal Circuit in its Hikma dispute, arguing that skinny-label carve-outs do not shield generics from inducement liability when broader marketing conduct encourages patented uses.
Generics Bulletin - April 2, 2026
Amid Iran War, India Tries To Keep Lights On With Duty Cuts
India has cut import duty on 40 petrochemical products to nil and reduced rates on domestic sales from SEZs as input, freight costs rise due to the Iran war. The Essential Commodities Act might also be invoked, but how much of an impact will it have on pharma?
Scrip - April 2, 2026
India has cut import duty on 40 petrochemical products to nil and reduced rates on domestic sales from SEZs as input, freight costs rise due to the Iran war. The Essential Commodities Act might also be invoked, but how much of an impact will it have on pharma?
Scrip - April 2, 2026
China Issues Global-First Approval For SPECT/CT Imaging Agent For Tumor Diagnosis
The technetium-99m labeled, integrin ?V?3-targeting 99mTc-3PRGD2 has been approved in China as the world’s first SPECT/CT imaging agent for the diagnosis of tumors.
Medtech Insight - April 2, 2026
The technetium-99m labeled, integrin ?V?3-targeting 99mTc-3PRGD2 has been approved in China as the world’s first SPECT/CT imaging agent for the diagnosis of tumors.
Medtech Insight - April 2, 2026
Europe’s Biotech Edge Lies In Science-First Investing
Despite tough markets and geopolitical uncertainty, Matthieu Coutet sees strong deal flow, rising investor appetite and big opportunities in fibrosis, with Sofinnova Partners taking an active role in building companies through series A and beyond.
In Vivo - April 2, 2026
Despite tough markets and geopolitical uncertainty, Matthieu Coutet sees strong deal flow, rising investor appetite and big opportunities in fibrosis, with Sofinnova Partners taking an active role in building companies through series A and beyond.
In Vivo - April 2, 2026
CIR Needs Phthalates Concentration Information
If and when CIR receives concentration of use data, it can calculate margins of exposure, which will help its expert panel assess the ingredients in light of potential endocrine disruption concerns for dibutyl and dimethyl.
HBW Insight - April 2, 2026
If and when CIR receives concentration of use data, it can calculate margins of exposure, which will help its expert panel assess the ingredients in light of potential endocrine disruption concerns for dibutyl and dimethyl.
HBW Insight - April 2, 2026
Tanabe Eyes US NDA For Dersimelagon Following Positive Phase III Results In Rare Derma Disorders
Tanabe plans US NDA for first oral option for rare skin disorders EPP and XLP, as it looks to fill gap from Radicava divestment and overcome regulatory challenges for some other late-stage candidates.
Scrip - April 2, 2026
Tanabe plans US NDA for first oral option for rare skin disorders EPP and XLP, as it looks to fill gap from Radicava divestment and overcome regulatory challenges for some other late-stage candidates.
Scrip - April 2, 2026
Trump 100% Tariffs On Drugs Make Big Pharma’s Negotiations A Smart Play
Most big pharmas – the companies that tend to have a global manufacturing network – are exempt from the US government’s Section 232 tariffs on pharmaceuticals.
Scrip - April 2, 2026
Most big pharmas – the companies that tend to have a global manufacturing network – are exempt from the US government’s Section 232 tariffs on pharmaceuticals.
Scrip - April 2, 2026
March Surge Lifts First Quarter M&A Totals To Recent Highs
The biopharma sector announced 41 merger-and-acquisition deals during Q1 2026, according to Evaluate, with a late March run of multibillion-dollar bids.
Scrip - April 2, 2026
The biopharma sector announced 41 merger-and-acquisition deals during Q1 2026, according to Evaluate, with a late March run of multibillion-dollar bids.
Scrip - April 2, 2026
Beam Preps For Commercialization Of Risto-Cel As Full Data Published
The publication included additional details on a patient whose death in the study had drawn analysts’ attention, revealing that he had a history of vaping as well as other conditions.
Scrip - April 2, 2026
The publication included additional details on a patient whose death in the study had drawn analysts’ attention, revealing that he had a history of vaping as well as other conditions.
Scrip - April 2, 2026
Roivant Shrugs Off Batoclimab Phase III Failure in TED
Immunovant’s first-generation FcRn inhibitor, batoclimab, has failed a pair of Phase III studies, prompting the company to undertake a review of the drug’s development program.
Scrip - April 2, 2026
Immunovant’s first-generation FcRn inhibitor, batoclimab, has failed a pair of Phase III studies, prompting the company to undertake a review of the drug’s development program.
Scrip - April 2, 2026
Alto’s Schizophrenia Failure Reinforces Its Depression Drive
Alto Neuroscience’s ALTO-101 has missed significance in a proof-of-concept study in schizophrenia patients, prompting the firm to stand even more squarely behind its lead depression asset, ALTO-207.
Scrip - April 2, 2026
Alto Neuroscience’s ALTO-101 has missed significance in a proof-of-concept study in schizophrenia patients, prompting the firm to stand even more squarely behind its lead depression asset, ALTO-207.
Scrip - April 2, 2026
Amid Iran War, India Tries To Keep Lights On With Duty Cuts
India has cut import duty on 40 petrochemical products to nil and reduced rates on domestic sales from SEZs as input, freight costs rise due to the Iran war. The Essential Commodities Act might also be invoked, but how much of an impact will it have on pharma?
Scrip - April 2, 2026
India has cut import duty on 40 petrochemical products to nil and reduced rates on domestic sales from SEZs as input, freight costs rise due to the Iran war. The Essential Commodities Act might also be invoked, but how much of an impact will it have on pharma?
Scrip - April 2, 2026
Tanabe Eyes US NDA For Dersimelagon Following Positive Phase III Results In Rare Derma Disorders
Tanabe plans US NDA for first oral option for rare skin disorders EPP and XLP, as it looks to fill gap from Radicava divestment and overcome regulatory challenges for some other late-stage candidates.
Scrip - April 2, 2026
Tanabe plans US NDA for first oral option for rare skin disorders EPP and XLP, as it looks to fill gap from Radicava divestment and overcome regulatory challenges for some other late-stage candidates.
Scrip - April 2, 2026
Execs On The Move: March 23–27, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 2, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 2, 2026
Whoop Raises $575M At $10.1Bn Valuation With Abbott on Board As Oura And Google Close In
The company, which ships to 56 countries and operates in six languages, said it ended last year booking deals at an annual pace of about $1.1 billion– up 103% year over year – and said it is hiring for more than 600 new roles globally in 2026.
Medtech Insight - April 2, 2026
The company, which ships to 56 countries and operates in six languages, said it ended last year booking deals at an annual pace of about $1.1 billion– up 103% year over year – and said it is hiring for more than 600 new roles globally in 2026.
Medtech Insight - April 2, 2026
Force Majeure, 35% Spike In Plastics Costs: Middle East Conflict Hits Medical Supply Chains
Five weeks into the Middle Eastern war, petrochemical force majeure declarations are being filed, prices for a key petrochemical used in plastics are up 35% and the supply chains that produce IV bags, syringes and catheters are under compounding pressure.
Medtech Insight - April 2, 2026
Five weeks into the Middle Eastern war, petrochemical force majeure declarations are being filed, prices for a key petrochemical used in plastics are up 35% and the supply chains that produce IV bags, syringes and catheters are under compounding pressure.
Medtech Insight - April 2, 2026
China Issues Global-First Approval For SPECT/CT Imaging Agent For Tumor Diagnosis
The technetium-99m labeled, integrin ?V?3-targeting 99mTc-3PRGD2 has been approved in China as the world’s first SPECT/CT imaging agent for the diagnosis of tumors.
Medtech Insight - April 2, 2026
The technetium-99m labeled, integrin ?V?3-targeting 99mTc-3PRGD2 has been approved in China as the world’s first SPECT/CT imaging agent for the diagnosis of tumors.
Medtech Insight - April 2, 2026
US Consumer Health People News: Primo For Griffey, HealthyBaby First President, More
Primo scores on hydration with Griffey; HealthyBaby names first president; Supergoop! Expands executive office with HR chief; and interim CFO at Nu Skin.
HBW Insight - April 2, 2026
Primo scores on hydration with Griffey; HealthyBaby names first president; Supergoop! Expands executive office with HR chief; and interim CFO at Nu Skin.
HBW Insight - April 2, 2026
Enzymatica Partners With Stada For German ColdZyme Launch
Stada will launch Enzymatica's virus-blocking oral spray ColdZyme under its own brand in Germany and Austria during the 2026/27 cold & flu season.
HBW Insight - April 2, 2026
Stada will launch Enzymatica's virus-blocking oral spray ColdZyme under its own brand in Germany and Austria during the 2026/27 cold & flu season.
HBW Insight - April 2, 2026
CIR Needs Phthalates Concentration Information
If and when CIR receives concentration of use data, it can calculate margins of exposure, which will help its expert panel assess the ingredients in light of potential endocrine disruption concerns for dibutyl and dimethyl.
HBW Insight - April 2, 2026
If and when CIR receives concentration of use data, it can calculate margins of exposure, which will help its expert panel assess the ingredients in light of potential endocrine disruption concerns for dibutyl and dimethyl.
HBW Insight - April 2, 2026
Who’s Hired? Watson Returns As Apotex CEO
The latest off-patent industry appointments have seen Jeff Watson return as president and CEO of Apotex and Pamela Hoffman take the title of CEO of Padagis, while Australia’s GBMA and Medicines for Ireland have announced new leadership.
Generics Bulletin - April 2, 2026
The latest off-patent industry appointments have seen Jeff Watson return as president and CEO of Apotex and Pamela Hoffman take the title of CEO of Padagis, while Australia’s GBMA and Medicines for Ireland have announced new leadership.
Generics Bulletin - April 2, 2026
Teva Clarifies Operations Stable After Neot Hovav Strike
Teva has confirmed no operational impact after a missile-related incident near its Neot Hovav site, countering reports that raised concerns over supply chain risk and manufacturing resilience amid escalating regional tensions.
Generics Bulletin - April 2, 2026
Teva has confirmed no operational impact after a missile-related incident near its Neot Hovav site, countering reports that raised concerns over supply chain risk and manufacturing resilience amid escalating regional tensions.
Generics Bulletin - April 2, 2026
Amarin Insists Skinny Labels Are Not A Safe Harbor
Amarin is asking the US Supreme Court to uphold the Federal Circuit in its Hikma dispute, arguing that skinny-label carve-outs do not shield generics from inducement liability when broader marketing conduct encourages patented uses.
Generics Bulletin - April 2, 2026
Amarin is asking the US Supreme Court to uphold the Federal Circuit in its Hikma dispute, arguing that skinny-label carve-outs do not shield generics from inducement liability when broader marketing conduct encourages patented uses.
Generics Bulletin - April 2, 2026
Europe’s Biotech Edge Lies In Science-First Investing
Despite tough markets and geopolitical uncertainty, Matthieu Coutet sees strong deal flow, rising investor appetite and big opportunities in fibrosis, with Sofinnova Partners taking an active role in building companies through series A and beyond.
In Vivo - April 2, 2026
Despite tough markets and geopolitical uncertainty, Matthieu Coutet sees strong deal flow, rising investor appetite and big opportunities in fibrosis, with Sofinnova Partners taking an active role in building companies through series A and beyond.
In Vivo - April 2, 2026